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Abstract
Background: Triple therapy is the gold standard treatment for Helicobacter pylori eradication from the human
stomach, but increased resistance to clarithromycin became the main factor of treatment failure. Until now,
fastidious culturing methods are generally the method of choice to assess resistance status. In this study, a new
genotypic method to detect clarithromycin resistance in clinical samples, based on fluorescent in situ hybridization
(FISH) using a set of peptide nucleic acid probes (PNA), is proposed.
Results: The set of probes targeting the point mutations responsible for clarithromycin resistance was applied to
H. pylori suspensions and showed 100% sensitivity and specificity (95% CI, 79.9-100 and 95% CI, 71.6-100
respectively). This method can also be amenable for application to gastric biopsy samples, as resistance to
clarithromycin was also detected when histological slides were tested.
Conclusions: The optimized PNA-FISH based diagnostic method to detect H. pylori clarithromycin resistance
shown to be a very sensitive and specific method for the detection of clarithromycin resistance in the H. pylori
smears and also proved to be a reliable method for the diagnosis of this pathogen in clinical samples and an
alternative to existing plating methods.
Background
Helicobacter pylori is well known for its ability to colo-
nize human stomach and, while most human carriers
are asymptomatic, colonization can lead to the develop-
ment of several gastric diseases, such as peptic ulcer dis-
ease, gastric mucosa-associated lymphoid tissue (MALT)
lymphoma and gastric carcinoma.
The over-usage of antimicrobial compounds has led to
an increase of H. pylori resistance to antibiotics and
consequent failure in treatment therapy [1,2]. In accor-
dance with the Maastricht Consensus in Europe, the
recommended therapy for H. pylori eradication in the
stomach mucosa is the use of a proton pump inhibitor
associated with two antibiotics, such as metronidazole,
amoxicillin or clarithromycin for a 7-14 days period [3].
This therapy, although highly effective, is unselectively
proposed to all patients and can imply serious discom-
fort to patients due to side effects of the antibiotics.
Clarithromycin resistance is one of the most prevalent
and can reach up to 20% in Southern European coun-
tries [1]. The resistance is associated with point muta-
tions in the peptidyltransferase region encoded in
domain V of the H. pylori 23S rRNA gene [2,4,5]. The
three most prevalent point mutations are the transitions
A2142G and A2143G and the transversion A2142C
[1,2,4]. Until now, the antibiotic susceptibility has been
detected in clinical laboratories by several phenotypical
methods such as the agar dilution method, as recom-
mended by the National Committee for Clinical Labora-
tory Standards (NCCLS) [6], or the alternative E-test
that is considered to be more simple [7-10]. However,
these methods are fastidious, time consuming [11], and
fail to give any information about the point mutation
within the sample [3]. Therefore, molecular methods for
the detection of clarithromycin resistance in H. pylori
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order to overcome these shortcomings. Polymerase
chain reaction (PCR) followed by sequencing or reverse
hybridization, Real-Time PCR and fluorescence in situ
hybridization (FISH) with DNA probes are some exam-
ples [2,9,12,13]. When compared to PCR-based meth-
ods, the FISH technique presents some advantages since
it is not so easily affected by DNA contamination, and
allows for direct visualization of bacteria in the gastric
biopsy specimens [1,2]. Recently, peptide nucleic acid
(PNA) probes using FISH have been designed and opti-
mized for the detection of several bacteria, such as
Enterobacter sakazakii, Pseudomonas aeruginosa and
Eschericia coli [14,15]. PNA molecules are DNA mimics
that have the negatively charged sugar-phosphate back-
bone replaced by an achiral, neutral polyamide backbone
formed by repetitive N-(2-aminoethyl) glycine units
[16,17]. Although PNA lacks pentoses, specific hybridi-
zation between the PNA sequences and nucleic acid
complementary sequences still occur according to the
Watson-Crick rules [18,19]. The neutral PNA molecule
characteristic is responsible for a higher thermal stability
(high Tm) between PNA/DNA or PNA/RNA bonding,
compared with the traditional DNA probes [17]. Due to
this high affinity, PNA probes normally have sequences
relatively smaller (13-18 nucleotides) than DNA
sequences (at least 18 nucleotides). Moreover, the PNA
molecules present more resistance to nucleases and pro-
teases than DNA molecules. When PNA probes are
attached to a fluorochrome dye, they can be detected by
epifluorescence microscopy or flow cytometry using the
fluorescence in situ hybridization (FISH) method
[16,17,20]. In earlier studies [19], this technique has pro-
vided more prompt and robust results in clinical and
environmental samples than the traditional culture
methods and it has been applied in a wide range of
microbiology fields [14,18]. In fact, a PNA-FISH method
to determine the presence of H. pylori in gastric biopsy
specimens has been already developed in our laboratory,
using a specific probe (Hp769) [21]. Due to the impor-
tance of antibiotic resistance, the aim of this work was
to develop and validate a new PNA-FISH based diagnos-
tic method to detect H. pylori clarithromycin resistance
directly in paraffin embedded gastric biopsies.
Methods
Bacterial strains and growth conditions
Thirty three H. pylori strains (31 clinical isolates and 2
collection strains), that had their clarithromycin resis-
tance profile determined in this study by sequencing
and E-test (see method description below), were used.
All strains were maintained on Columbia Agar Base
(Liofilchem s.r.l., Roseto D.A., Italy) supplemented with
5% (vol/vol) defibrinated horse blood (Probiológica,
Belas, Portugal). Single colonies were streaked onto
fresh media every 2 or 3 days, and the plates were incu-
bated in a CO2 incubator (HERAcell 150
®;T h e r m o
Electron Corporation, Waltham, MA, USA) set to 10%
CO2 and 5% O2, at 37°C [21,22].
Design of PNA oligonucleotide probes for the detection
of clarithromycin resistance
PNA probes were designed by adapting the already
existing DNA probes, targeting the region of the point
mutations described for this antibiotic in H. pylori [2].
Since PNA probes usually present higher melting tem-
peratures it was possible to design shorter sequences
with 15 nucleotides. The selected probes were Hp1
(A2143G) 5’-GGG TCT CTC CGT CTT-3’,H p 2
(A2142G) 5’- G G GT C TT C CC G TC T T - 3 ’ and Hp3
(A2142C) 5’-GGG TCT TGC CGT CTT-3’.A na d d i -
tional probe to detect wild type strains (Hpwt 5’-GGG
TCT TTC CGT CTT-3’) was also included. Afterwards,
the selected sequences were synthesized (Panagene, Dae-
jeon, South Korea). The N terminus of the Hp1, Hp2
and Hp3 oligomers was connected to Alexa Fluor 488,
and that of the Hpwt connected to Alexa Fluor 594, all
via a double AminoEthoxyEthoxy Acetyl linker.
Fluorescence in situ hybridization
As a starting point for the optimization of hybridization
conditions the protocol previously described was used
[14,21]. Since the different probes only differed in one
nucleobase, and for multiplex purposes, a common
hybridization temperature was expected for all probes.
Based on the brightest signals and specificity of the
results, the best performance was obtained at 70°C (data
not shown). H. pylori sensitive or resistant strain sus-
pensions were prepared in water and 20 μl of each sus-
pension was dispensed in 8 mm well slides (Marienfeld,
Lauda-Königshofen, Germany) and then allowed to air
dry. For permeabilization and fixation of bacteria, 30 μl
of 4% paraformaldehyde (wt/vol) were placed in the
wells with care to cover the entire surface, followed by
50% (vol/vol) ethanol for 10 minutes each, and then
allowed to air dry. Approximately 20 μl of hybridization
solution containing a mixture of the four probes were
added to the fixed smears, which were then covered
with coverslips and incubated for 1 hour at 70°C. Each 1
ml of hybridization solution contained 200 nM of the
probes mixture, 10% (wt/vol) dextran sulphate, 10 mM
NaCl, 30% (v/v) formamide, 0.1% (wt/vol) sodium pyro-
phosphate, 0.2% (wt/vol) polyvinylpyrrolidone, 0.2% (wt/
vol) FICOLL, 5 mM disodium EDTA, 0.1% (vol/vol) Tri-
ton X-100 and 50 mM Tris-HCl (all from Sigma-
Aldrich, Sintra, Portugal, except disodium EDTA that
was from Pronalab, Lisbon, Portugal). Subsequently, the
slides were transferred to a Coplin jar containing
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mM Tris Base, 15 mM NaCl and 1% (vol/vol) Triton X-
100 (all from Sigma-Aldrich, Sintra, Portugal), where the
coverslips were carefully removed. The washing step was
carried out for 30 minutes at 70°C. The slides were
allowed to air dry and mounted with one drop of
mounting oil and covered with a coverslip.
Specificity and sensitivity of PNA probes
After optimizing hybridization conditions, experiments
with the PNA-FISH were performed on the 33 available
strains in order to confirm the practical specificity and
sensitivity of the probes. These results were compared
with the gold standard susceptibility culturing test (E-
test) and with the presence/absence of mutations in the
23S rRNA gene.
Validation of the testing protocol in gastric biopsy slides
for clinical application
To validate the method in the stomach tissue, thirty
nine paraffin-embedded gastric biopsy specimens from
patients with known resistance antibiotic profile by anti-
biogram were used. The study was in accordance with
the institutional ethical standards. Informed consent was
obtained from the patients. Three-micrometer thick par-
affin cuts were deparaffinized and rehydrated in xylol
and ethanol based on a protocol previously described
[21]. Sections were emerged in xylol (Fisher Chemical,
Leicestershire, U.K.) three times (firstly for 15 minutes,
and then twice for 10 minutes each), absolute ethanol
(Panreac, Barcelona, Spain) (twice for 7.5 minutes each)
and ethanol decreasing concentrations (95%, twice for
7.5 minutes each; 80%, 10 minutes; 70%, 10 minutes;
50%, twice for 15 minutes each). Finally sections were
immersed in 1% (vol/vol) Triton X-100 (Sigma-Aldrich,
Sintra, Portugal) solution for 20 minutes at 70°C. Histo-
logical slides were then allowed to air dry and the hybri-
dization protocol previously described for smears, with
the exclusion of the fixation step, was used. The com-
pletion of the whole procedure takes 4 h 15 m.
Susceptibly test: E-test
In order to confirm the susceptibility profile, the mini-
mal inhibitory concentration (MIC) of each strain was
determined by the E-test, in accordance with the com-
pany instructions (AB Biodisk, Biomérieux, Portugal).
Briefly, 2 day-old pure cultures were inoculated into
Mueller-Hinton broth, supplemented with 5% (vol/vol)
fetal calf serum [23] and the turbidity of the inoculum
adjusted to McFarland standard 3 [7]. Agar plates con-
taining Mueller-Hinton supplemented with 5% (vol/vol)
defibrinated horse blood (Probiológica, Belas, Portugal)
were inoculated by swabbing the surface with the
inocula. One E-test strip was applied on the surface of
the plate, after drying. The plates were incubated in a
CO2 incubator (HERAcell 150
®; Thermo Electron Cor-
poration, Waltham, MA, USA) set to 10% CO2 and 5%
O2 at 37°C for 72 h or until visible inhibition ellipse was
seen [2,7,23]. Strains were considered susceptible when
the MIC was < 1 μg/ml, and resistant when the MIC
was > 1 μg/ml [9].
Assessment of clarithromycin resistance in gastric tissues
by PCR and sequencing
Total DNA was extracted from biopsy samples after
digestion with Proteinase K for at least 12 hours at 55°
C. Proteinase K was inactivated by incubation at 95°C
for 10 minutes. Ten microliters of the lysates were used
for PCR amplification of H. pylori 23S rRNA gene as
previously described [24]. PCR products were sequenced
using BigDye Terminator v3.1 Cycle Sequencing Kits
(Applied Biosystems, CA, USA) and run in an ABI
Prism 3130 DNA automated sequencer (Applied Biosys-
tems). In some H. pylori isolates, PCR and sequencing
were used to characterize the 23S rRNA gene.
Microscopic visualization
Visualization of samples never exceeded 48 h after the
experimental procedure. Smears or histological slides
were observed using an epifluorescence microscope
(BX51 Olympus, Hamburg, Germany) equipped with fil-
ters adapted to the Alexa Fluor (488 and 594) signalling
molecules within the probes. The filters that were not
sensitive for the reporter molecules were used as nega-
tive control.
Results and Discussion
Specificity and sensitivity of the PNA-FISH probes
In order to confirm the practical specificity and sensitiv-
ity of the probes, PNA-FISH was performed on the 33
available strains (table 1). The original genotyping of the
strains was confirmed by sequencing, and 20 isolates
were identified as clarithromycin resistant. Of these, 10
presented the A2143G mutation, eight the A2142G
mutation and one the A2142C mutation. In one case,
different genotypes in the same strain (WT and
A2143G) were observed, and this strain was considered
resistant. The comparison between PNA-FISH and
sequencing showed a correlation of 100%.
There are other less prevalent point mutations
referred in the literature [25-28], but are surrounded by
controversy since their association to clarithromycin
resistance have not been definitely proved [1,29]. In
addition to that, some reports presented clarithromycin
resistance mechanisms other than point mutations, such
as efflux pumps or rRNA methylation [30] that can be
revealed with phenotypic methods, although they are
not detected by genotypic methods that are specific to
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described. In the present manuscript, one of the strains
tested gave different results between E-test (MIC 32 μg/
ml) and PNA-FISH (only hybridized with the Hpwt)
showing 95.5% of similarity between the two methods
(table 2). This apparently discrepant observation may be
attributed to the presence of other 23S rRNA gene
mutations known to confer phenotypic resistance or,
alternatively, to additional mechanisms of resistance.
Despite this decrease in sensitivity, it is known that the
three mutations referred to in this study were revealed
to be the more frequently associated with macrolide
resistance. De Francesco and co-workers [30] stated that
more than 90% of primary clarithromycin resistance
strains from western countries are related with A2142G,
A2142C and A2143G mutations.
From the three mutations, the one that is less frequent
is the A2142C transversion [1,12], and in this study we
were only able to test one strain with that mutation.
Nevertheless, the available strain was always detected
when the Hp3 probe was present in the hybridization
solution. Probes Hp1, Hp2, and Hp3, hybridized only
with the resistant strains that had the corresponding
point mutations conferring clarithromycin resistance
and as such presented 100% sensitivity (95% CI, 79.9-
100) and 100% specificity (95% CI, 71.6-100). The set of
probes can discriminate the resistant and susceptible
strains, even though they only have one mismatch. We
next further tested the method using a mixture of the
four probes simultaneously in a multiplex detection
(figure 1; A-C). In this case, the detection of point
mutations was even more robust, which is possibly due
to the fact that all probes target the same locus, and as
such there is a competition effect between them. How-
ever, with the mixture it is only possible to discriminate
between clarithromycin resistant and clarithromycin
sensitive strains, as opposed to the discrimination
between point mutations that was conferred by using
the probes separately. In practical terms and considering
the application of the PNA-FISH to the clinical setting,
the mixture of probes introduces an important simplifi-
cation to the method.
Validation of the testing protocol in gastric biopsy slides
for clinical application
Considering the application of the PNA-FISH method in
clinical settings, we used the developed PNA probes to
identify and differentiate clarithromycin resistant and
susceptible H. pylori strains in histological slides of gas-
tric biopsy samples. Results clearly show that it is possi-
ble to discriminate susceptible from resistant H. pylori
Table 1 PCR, E-test and FISH results of the detection of
clarithromycin resistance in H. pylori clinical isolates
Strain Genotype PCR E-test PNA-FISH
3939
1 WT S S S
2277
1 WT S R S
2406
1 WT S S S
2424
1 WT S S S
3183
1 WT S S S
3131
1 WT S S S
3148
1 WT S S S
2452A
1 WT S S S
2448
1 WT S S S
2708
1 A2142G R R R
2712
1 A2142G R R R
3941
1 WT/A2143G R R R
2191
1 A2143G R R R
2009
1 A2143G R R R
1162
1 A2143G R R R
1987
1 A2143G R R R
2053
1 A2143G R R R
2538
1 A2143G R R R
2539
1 A2143G R R R
2768
1 A2143G R R R
166
2 A2142C R R R
167
2 A2143G R R R
168
2 A2142G R R R
169
2 WT S S S
7.83
3 A2143G R R R
7.11
3 A2142G R R R
7.38
3 A2142G R R R
6271
3 A2142G R R R
7.36
3 A2142G R R R
6231
3 A2142G R R R
968
1 WT S S S
NCTC 11637
4 WT S S S
ATCC 700392
4 WT S S S
Some strains were also sequenced in our labs to guarantee that no
contamination had occurred during culture maintenance
1 Dr. M. Oleastro (National Institute of Health, Lisbon, Portugal);
2Dr. R. Haas
(Max von Pettenkofer Institute for Hygiene and Medical Microbiology, Ludwig
Maximilians University of Munich, Germany);
3Dr. G. Perez-Perez (NYU
Langone Medical Center, New York, USA);
4 Type strain; R: Clarithromycin
resistant (MIC > 1 μg/ml); S: Clarithromycin susceptible (MIC < 1 μg/ml); WT:
Wild Type.
Table 2 Comparison between PNA-FISH methodology,
PCR-sequencing and E-test for detection of
clarithromycin resistance in 33 H. pylori strains
PNA-FISH
Resistant Susceptible
E-test
Resistant (21) 20 1
Susceptible (12) 0 12
PCR-sequencing
Resistant (20) 20 0
Susceptible (13) 0 13
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Page 4 of 7Figure 1 PNA-FISH detection. A)-C) In smears: A) Susceptible strain in the red channel; B) Resistant strain in the same microscopic field in the
green channel; C) Superimposition of both channels. D)-K) In gastric biopsy histological slides. D) Strain visualization using the Hp1 (A2143G)
PNA probe; F) Hp2 (A2142G) PNA probe; H) Hp3 (A2142C) PNA probe; K) Hpwt (wild type strain) PNA probe; E),G),I) Visualization of the same
microscopic field of D),F),H) with the red channel (negative controls for Hp1, Hp2 and Hp3); J) Visualization of the same microscopic field of K)
with the green channel (negative control for Hpwt). Arrows indicate the presence of H. pylori infecting the gastric mucosa. (Original
magnification × 600).
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Page 5 of 7strains and, in the latter group, to detect the three dif-
ferent mutations, using fluorescence microscopy (figure
1; D-K). Taking into consideration the antibiogram as
the gold standard, the PNA-FISH method showed speci-
ficity and sensitivity of 90.9% (95% CI, 57.1-99.5) and
84.2% (95% CI, 59.5-95.8), respectively (data not shown).
These can probably be explained by the existence of
another mechanism of resistance apart from the three
point mutations assessed in this study. In fact, associa-
tion between A2142C, A2142G and A2143G mutations
and clarithromycin resistance was defined as approxi-
mately 84% in a world wide data compilation [3].
Although, these results need to be confirmed in a lar-
ger series of cases, they indicate that PNA-FISH is
applicable to clinical samples and may be useful for the
selection of the most adequate antibiotic combination to
be used for H. pylori eradication. Moreover, this method
is simple to perform and the procedure is fast (4 h 15
m), indicating that results can be provided to clinicians
simultaneously with the histological diagnosis.
Conclusions
Resistance to antibiotics, namely to clarithromycin, is one
of the causes of treatment failure in H. pylori eradication
[1]. For this reason, it is the most beneficial to detect resis-
tance to clarithromycin prior to antibiotic therapy. Stan-
dard culturing methods (E-test, agar dilution) have been
used for this purpose, despite several shortcomings: these
methods are time consuming and H. pylori is difficult to
grow in culture; there is the risk of contamination of sam-
ples during transportation leading to overgrowth of other
bacteria that may mask the growth of H. pylori;t h e s e
methods do not provide any information regarding the
specific point mutation(s) in each resistant strain [12].
Other alternative molecular based methods require DNA
extraction followed by PCR amplification and sequencing
for the identification of the mutation(s) [4,9,13].
Herein we describe the applicability of PNA-FISH
methodology to clinical material, namely gastric biopsy
samples [2,21], thus overcoming the need of culturing
steps and/or PCR/sequencing procedures and enabling
rapid initiation of appropriate antibiotic therapy until
culture confirmation can be obtained several days later
[1]. Furthermore, the required equipment, a fluorescent
microscope equipped with adequate filters for fluoro-
chromes, is easy to handle for routine diagnostic pur-
poses. For centres using routine cultures of H. pylori,
the complementary use of PNA-FISH methodology to
smears of bacteria will increase the sensitivity of the
detection of resistant strains in clinical samples.
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